Results 141 to 150 of about 31,146 (236)
Background and Purpose Episodic ataxia type 1 (EA1) is an autosomal dominant neurological disorder caused primarily by loss‐of‐function mutations in the voltage‐gated potassium channel Kv1.1 (KCNA1). Small molecules that restore Kv1.1 activity hold promise as targeted therapies for EA1, yet current pharmacological strategies remain limited ...
Rían W. Manville +6 more
wiley +1 more source
Abstract Doxorubicin (DOX) is a potent anthracycline chemotherapeutic agent, but its clinical use is limited by cumulative cardiotoxicity. Exercise, particularly high‐intensity interval training (HIIT), has emerged as an effective non‐pharmacological strategy to counteract chemotherapy‐induced cardiac injury.
Mahdiyeh Farahani +3 more
wiley +1 more source
Background: Cancer chemotherapy increases the risk of heart failure. This cost-effectiveness model compared strain-guided cardioprotection with other protective strategies using a health care payer perspective and five-year time horizon.
Nolan, Mark T. +5 more
core +1 more source
It has been shown that ischemia preconditioning(IPC)can attenuate the myocardial injury induced by ischemic and reperfusion.But it was rarely used in clinic due to its inoperability.Previous studies indicate that electroacupuncture(EA)pretreatment can ...
DAI Qiu-fu +10 more
doaj +2 more sources
The role of signal transducer and activator of transcription-3 (STAT-3) in ischaemic and pharmacological postconditioning [PDF]
Includes abstract. Includes bibliographical references (leaves 131-147)
Somers, Sarin J
core
A link between ATP and SUR2A:a novel mechanism explaining cardioprotection at high altitude [PDF]
Sukhodub, Andriy +4 more
core +1 more source
SURPASS‐CVOT and the Emerging Biology of Cardiometabolic Benefit
Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 8753-8756, October 2026.
Salvatore Corrao +2 more
wiley +1 more source
USAGE OF CARDIOPROTECTION PRINCIPLES IN TREATING CHRONIC HEART FAILURE
Usage of cardioprotection principles in treating chronic heart failure.
M. A. Gurevich, N. P. Sanina
doaj
Reperfusion Injury and Infarct Size: Why Translation has Been Difficult, and How We Move Forward. [PDF]
Bulluck H, Hausenloy DJ.
europepmc +1 more source
Historical account of reperfusion therapy and the development of cardioprotection beyond reperfusion. [PDF]
Heusch G, Kleinbongard P, Gersh BJ.
europepmc +1 more source

